Months af­ter strik­ing SHP2 deal with Ab­b­Vie, Ja­co­bio pulls in $174M+ from Hong Kong IPO

The sea­soned crew at Ja­co­bio has raised $174.1 mil­lion on its HKEX de­but, fu­elling a pipeline an­chored by two Ab­b­Vie-part­nered al­losteric SHP2 in­hibitors.

It’s sig­nif­i­cant­ly less than what the biotech was ru­mored to be seek­ing back in Au­gust — Bloomberg’s sources said it could be as much as $400 mil­lion — but Qim­ing, which has backed the biotech since its Se­ries A, was hap­py about how it went from found­ing to IPO in just five years. At 12.34%, Qim­ing owned the largest chunk of stock in Ja­co­bio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER